Raymond James Maintains Outperform on Medtronic, Raises Price Target to $142
Raymond James analyst Jayson Bedford maintains Medtronic (NYSE:MDT) with a Outperform and raises the price target from $135 to $142.
Wells Fargo Maintains Overweight on Medtronic, Raises Price Target to $151
Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $140 to $151.
Credit Suisse Maintains Outperform on Medtronic, Raises Price Target to $146
Credit Suisse analyst Matt Miksic maintains Medtronic (NYSE:MDT) with a Outperform and raises the price target from $137 to $146.
Medtronic Wins FDA Approval Of Next-Gen TAVR System For Aortic Stenosis
The FDA has approved Medtronic plc’s (NYSE:MDT) Evolut FX TAVR system, a self-expanding transcatheter aortic valve replacement (TAVR) system. The Evolut…
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning session, 95 companies made new 52-week highs.
Medtronic Announces FDA Approval Of Next-Gen TAVR System For Treatment Of Symptomatic Severe Aortic Stenosis
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR)
Medtronic Q1 Earnings Double As Elective Procedures Recover
Medtronic Plc’s (NYSE:MDT) Q1 FY22 sales of $7.9 billion increased 23% Y/Y as reported and 19% on an organic basis, beating…
The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 23)
Medtronic: Q1 Earnings Insights
Shares of Medtronic (NYSE:MDT) moved higher by 0.3% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 127.42% over the past year to $1.41, which beat the estimate of $1.32.